← Eichor
Study identifier: NCT07405164 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)

Condition: Von Hippel-Lindau Disease · Malignant Neoplasms  ·  Sponsor: Merck Sharp & Dohme LLC

PhasePhase 3
Planned participants450
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Researchers are looking for new ways to treat advanced solid tumors and von Hippel-Lindau (VHL)-related tumors: * Advanced means the cancer has spread to other parts of the body (metastatic) or cannot be removed with surgery * Solid tumors are cancers mostly in body organs and tissues, not in the blood or other body liquids * VHL-related tumors are tumors caused by VHL disease. VHL disease is passed down from parents to children and people with VHL disease have a higher chance of getting certain types of cancer Researchers want to learn about the long-term effects of a trial medicine called belzutifan. Belzutifan, also called MK-6482, is designed to block a protein that helps tumors grow and survive. This is an extension trial, which means only people who were in certain other belzutifan trials (called parent trials) may be able to join. The goal of this trial is to learn how long people live after they start taking belzutifan.

This description comes directly from the study's public registry record.

Talk to the study team

Toll Free Number  ·  1-888-577-8839  ·  Trialsites@msd.com

Always discuss trial participation with your own doctor first.

Locations (49)

Beth Israel Deaconess Medical Center ( Site 0107)Boston, Massachusetts, United StatesRecruiting
Dana-Farber Cancer Institute ( Site 0105)Boston, Massachusetts, United StatesRecruiting
Karmanos Cancer Center ( Site 0108)Detroit, Michigan, United StatesRecruiting
Hospital of the University of Pennsylvania Perelman Center for Advanced Medicine ( Site 0100)Philadelphia, Pennsylvania, United StatesRecruiting
SCRI Oncology Partners ( Site 7000)Nashville, Tennessee, United StatesRecruiting
START San Antonio ( Site 0104)San Antonio, Texas, United StatesRecruiting
Fred Hutchinson Cancer Center ( Site 0106)Seattle, Washington, United StatesRecruiting
St George Hospital-Oncology Clinical Research Unit ( Site 2701)Kogarah, New South Wales, AustraliaRecruiting
Westmead Hospital ( Site 2703)Sydney, New South Wales, AustraliaRecruiting
UZ Leuven ( Site 0900)Leuven, Vlaams-Brabant, BelgiumRecruiting
BP - A Beneficencia Portuguesa de São Paulo ( Site 0200)São Paulo, São Paulo, BrazilRecruiting
Département clinique de médecine de laboratoire du CHUM ( Site 0001)Montreal, Quebec, CanadaActive Not Recruiting

+ 37 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07405164